ZERO WORLD RESEARCHLiterature database on amino acids & organic acids

Possible Beneficial Actions of Caffeine in SARS-CoV-2.

International journal of molecular sciences2021Romero-Martínez BS, Montaño LM, Montaño LM, et al.
Study designReview
SubjectHuman

Record checks

Study design
Review
Subject
Human
Publication year
2021
Source
doi.org
Abstract display
Shown here
Publication status
Active
Status checked
17 Aug 2026
Collected
3 Aug 2026
Freshness
Current
Review stage
Automated
Record status
Published

Abstract

The COVID-19 pandemic has established an unparalleled necessity to rapidly find effective treatments for the illness; unfortunately, no specific treatment has been found yet. As this is a new emerging chaotic situation, already existing drugs have been suggested to ameliorate the infection of SARS-CoV-2. The consumption of caffeine has been suggested primarily because it improves exercise performance, reduces fatigue, and increases wakefulness and awareness. Caffeine has been proven to be an effective anti-inflammatory and immunomodulator. In airway smooth muscle, it has bronchodilator effects mainly due to its activity as a phosphodiesterase inhibitor and adenosine receptor antagonist. In addition, a recent published document has suggested the potential antiviral activity of this drug using in silico molecular dynamics and molecular docking; in this regard, caffeine might block the viral entrance into host cells by inhibiting the formation of a receptor-binding domain and the angiotensin-converting enzyme complex and, additionally, might reduce viral replication by the inhibition of the activity of 3-chymotrypsin-like proteases. Here, we discuss how caffeine through certain mechanisms of action could be beneficial in SARS-CoV-2. Nevertheless, further studies are required for validation through in vitro and in vivo models.

MeSH

Anti-Inflammatory AgentsAntiviral AgentsCOVID-19CaffeineDrug RepositioningHumansImmunologic FactorsMolecular Dynamics SimulationMuscle, SmoothPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesSARS-CoV-2

DOI 10.3390/ijms22115460

PMID 34067243

View source →